---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-005024"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T12:59:20.165077+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Elite Pharma Q3 revenue $9.3M (+3% YoY), net income $2.96M

## Summary
- Q3 FY2023 revenue $9.3M, up 3% from prior year; operating profit $2.0M.
- Net income for Q3 was $2.96M; nine-month net income $4.79M.
- Nine-month revenue $25.5M (+4% YoY); operating profit $4.1M (down $0.1M).
- Growth driven by generic immediate-release and extended-release Adderall.
- Conference call set for Feb 15, 2023 at 11:30 AM EST to discuss results.

## SEC filing metadata
- accession: 0001493152-23-005024
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315223005024/0001493152-23-005024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315223005024/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-005024
- JSON: https://secwatch.observer/filing/0001493152-23-005024.json
- Plain text: https://secwatch.observer/filing/0001493152-23-005024.txt

## Key facts
- Earnings Releases
  ELITE PHARMACEUTICALS INC /NV/ reported the nine-month period ended December 31, 2022 results: revenue $25.5 million, net income $4.79 million.
  - Period: the nine-month period ended December 31, 2022
  - Revenue: $25.5 million
  - Net income: $4.79 million
  - Result: reported results
  source text: Consolidated revenues for the nine-month period ended December 31, 2022, were $25.5 million, an increase of $0.90 million or 4% as compared to the comparable period of the prior fiscal year. The increase was primarily attributed to revenues from generic immediate-release Adderall ® and generic extended-release Adderall ® . Operating profits were $4.1 million, a decrease of $0.10 million from the comparable period of the prior year, and net income was $4.79 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053369/000149315223005024/0001493152-23-005024-index.htm
- Earnings Releases
  ELITE PHARMACEUTICALS INC /NV/ reported the third quarter of fiscal year 2023 ended December 31, 2022 results: revenue $9.3 million, net income $2.96 million.
  - Period: the third quarter of fiscal year 2023 ended December 31, 2022
  - Revenue: $9.3 million
  - Net income: $2.96 million
  - Result: reported results
  source text: Consolidated revenues for the three-month period ended December 31, 2022, were $9.3 million, an increase of $0.30 million or 3% as compared to the comparable period of the prior fiscal year. The increase was primarily attributed to revenues from generic immediate-release Adderall ® and generic extended-release Adderall ® . Operating profits were $2.0 million, an increase of $0.12 million from the prior year’s comparable period, and net income was $2.96 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053369/000149315223005024/0001493152-23-005024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.